We measure proteins and their modification using a nano-proteomic immunoassay (NIA).
We can measure direct biological effects on growth, death, and immune activation.
Our assays are highly sensitive (2 pgs, 4 nls, 25 cells) quantitative and reproducible (< 2% variation).
1. Alice C. Fan, Jennifer J. O’Rourke, Dave R. Praharaj, and Dean W. Felsher
Real-Time Nanoscale Proteomic Analysis of the Novel Multi-Kinase Pathway Inhibitor Rigosertib to Measure the Response to Treatment of Cancer
Expert Opin Investig Drugs. 2013
2. Mahesh Seetharam, Alice C. Fan, Mai Tran, Liwen Xu, John P. Renschler, Dean W. Felsher, Kunju Sridhar, Francois Wilhelm, Peter L. Greenberg,
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na
Leukemia Research 2012;
3. Ronan T. Swords, Ronan T. Swords, Peter L. Greenberg, Andrew H. Wei, Simon Durrant, Anjali S. Advani, Mark S. Hertzberg, Ian D. Lewis, Gabriel Rivera, Dita Gratzinger, Alice C. Fan, Dean W. Felsher, Jorge E. Cortes, Justin M. Watts, Geoff T. Yarranton, Jackie M. Walling, Jeffrey E. Lancet,
KB004, a first in class monoclonal antibody targeting the receptortyrosine kinase EphA3, in patients with advanced hematologicmalignancies: Results from a phase 1 study.
Leukemia Research 2016;
4. Alice C Fan, Debabrita Deb-Basu, Mathias W Orban, Jason R Gotlib, Yasodha Natkunam, Roger O’Neill, Rose-Ann Padua, Liwen Xu, Daryl Taketa, Amy E Shirer, Shelly Beer, Ada X Yee, David W Voehringer & Dean W Felsher
Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens
Nature Medicine 2009
5. Brian A. DeChristopher, Alice C. Fan, Dean W. Felsher, Paul A. Wender
“Picolog,” a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo
Oncotarget, January, 2012
Pdf free access: